A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
← catalyst calendarNCT06185764 · readout in 166 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
52estimated
Sites
26
Countries
Australia, Belgium, Canada +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-20 | actual | When the study began enrolling |
| Primary completion | 2027-02-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-02 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myotonic Dystrophy Type 1 (DM1)
Interventions
- Drug: VX-670
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFParts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
measured Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed